Citations

Clear

2303 citation(s) found for "Yu, Edward".

Computer automation for physics chart check should be adopted in clinic to replace manual chart checking for radiotherapy
Clouser, Edward , Chen, Quan , Rong, Yi , Clouser, Edward L, Rong, Yi , Clouser, Edward Lee

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 5, 2021 | Volume: 22 | Issue: 2 | Pages: 4-8

10.1002/acm2.13177 | PMID 33529445 Get It

Determination of Internal Forces in Human Hand
Chao, Edward , An, K.N.

Mayo Clinic

Journal of the Engineering Mechanics Division | February 3, 2021 | Volume: 104 | Issue: 1 | Pages: 255-272

10.1061/jmcea3.0002325 Get It

A Longitudinal Replicate Study of Immunosuppressive Drugs
Steele, Bernard W., Wang, Edward , Soldin, Steven J., Klee, George G., Elin, Ronald J., Witte, David L.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 127 | Issue: 3 | Pages: 283-288

10.5858/2003-127-0283-alrsoi | PMID 12653570 Get It

Abstract Objective.—To identify the sources of analytical variation for cyclosporine and tacrolimus in a 3-year longitudinal study. Design.—Two pools of whole blood were spiked with cyclosporine and tacrolimus, respectively. One aliquot of cyclosporine and 2 of the tacrolimus pool were distributed in the first and last mailing for years 1999 to 2001. For both drugs, the total variance for each method was partitioned into within- and between-laboratory components. Setting.—The A and C mailings of the 1999, 2000, and 2001 AACC/CAP [American Association for Clinical Chemistry/College of American Pathologists] Immunosuppressive Drugs (CS) Monitoring Survey. Main Outcome Measures.—For each drug, total variance was partitioned into specimen, mailing, year, and interlaboratory effects for each analytical method. Participants.—The 292 laboratories for cyclosporine and 177 laboratories for tacrolimus enrolled in the survey from 1999 to 2001. Results.—For both cyclosporine and tacrolimus, the major source of imprecision came from within-laboratory factors, which accounted for nearly 85% (range, 77% to 90%) of the total variance. For cyclosporine, the major component of within-laboratory variance was between-mailing, within-year effect, whereas for tacrolimus it was the between-year, within-laboratory variation. Conclusion.—The major source of long-term survey imprecision for cyclosporine and tacrolimus is within-laboratory factors. The finding that 85% of the total variance was due to within-laboratory variation is similar to other therapeutic drugs.
An Evaluation of Analytic Goals for Assays of Drugs
Steele, Bernard W., Wang, Edward , Klee, George G., Elin, Ronald J., Soldin, Steven J., Witte, David L., Richards, C. Sue

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 125 | Issue: 6 | Pages: 729-735

10.5858/2001-125-0729-aeoagf | PMID 11371222 Get It

Abstract Objective.—To determine if the levels of imprecision of the commonly used analytic methods for drug measurements are suitable for long-term therapeutic drug monitoring. Design.—In 1996, 4 identical lyophilized samples (2 in the first mailing and 2 in the second mailing 4 months later) were sent to laboratories participating in a nationwide proficiency testing program. Similarly, in 1999, replicates from a liquid pool of spiked sera were mailed 3 times, 4 months apart, to participating laboratories. For each of 11 drugs regulated under the Clinical Laboratory Improvement Amendments of 1988 and 1 metabolite, the total variance for each method was partitioned into within- and between-laboratory components. The total within-laboratory and the total survey coefficients of variation (CVs) for each method were then compared with the “acceptable” precision criteria of Glick, Burnett, and Fraser for each drug. Setting.—The first 2 mailings of the College of American Pathologists Therapeutic Drug Monitoring surveys for 1996, sets Z and ZM, and the 3 mailings of 1999, sets ZM, Z, and Z2. Main Outcome Measures.—For each drug studied, the CV of each method was compared with the various imprecision criteria, and if greater than any of the criteria, the method was then tabulated as not meeting that specific criterion. Participants.—The approximately 5000 participants of the survey. Results.—The number of methods deemed as not having acceptable total long-term within-laboratory precision by the various criteria ranged from 35% to 88% in 1996 and from 22% to 77% in 1999. Conclusion.—The number of failures possibly indicates that many of the reagent assays being utilized are not precise enough for long-term therapeutic drug monitoring of chronically administered drugs or that the published criteria used to evaluate the data in this study are too stringent.
Sources of Variability
Steele, Bernard W., Klee, George G., Elin, Ronald J., Witte, David L., Wang, Edward , Richards, C. Sue

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 125 | Issue: 2 | Pages: 183-190

10.5858/2001-125-0183-sov | PMID 11175632 Get It

Abstract Objective. —To determine the magnitudes and sources of analytic variation in testing for therapeutic drugs. Specifically, among laboratories using the same analytic method, to compare the within-laboratory variation (including both short- and long-term variation) with the between-laboratory variation. Design. —Four identical challenges were prepared from a lyophilized pool of spiked sera and were sent in pairs 4 months apart to laboratories participating in a nationwide proficiency-testing program. For each of 25 drugs, the variability in reported results from laboratories using the same method was investigated using nested analysis of variance. Setting. —The first 2 mailings of the College of American Pathologists Therapeutic Drug Monitoring Survey, 1996, sets Z and ZM. Main Outcome Measures. —For each drug, total variance was partitioned into within- and between-laboratory components for common methods. The within-laboratory component was further partitioned into short- and long-term components. Participants. —The approximately 5000 laboratories enrolled in the survey. Results. —For the 25 drugs, the average percentages of the total variance due to short-term, within-laboratory variance; long-term, within-laboratory variance; between-laboratory variance; and total laboratory variance were 25.0% (range, 8.8–50.6%), 57.8% (35.3–73.7%), 17.3% (5.0–35.4%), and 82.7% (64.6–95.0%), respectively. Conclusion. —For all drugs tested, the within-laboratory component of variance was greater than the between-laboratory component of variance. Within laboratories, the magnitude of the long-term component was generally greater than the magnitude of the short-term component. This information will be helpful in determining the clinical utility of various drug assays and in evaluating the appropriateness of regulations involving therapeutic drug testing.
Modeling autosomal dominant Alzheimer's disease with machine learning
Luckett, Patrick H. , McCullough, Austin , Gordon, Brian A. , Strain, Jeremy F. , Flores, Shaney , Dincer, Aylin , Kuffner, Todd A. , Stern, Ari, Meeker, Karin L. , Berman, Sarah , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Cash, David M. , Fulham, Michael , Jack, Clifford R. , Vöglein, Jonathan , Klunk, William E. , Oh, Hwamee , Swisher, Laura, Marcus, Daniel S. , Koudelis, Deborah, Joseph‐Mathurin, Nelly , Cash, Lisa, Hornbeck, Russ C. , Perrin, Richard J. , Hassenstab, Jason , Morris, John C. , Bateman, Randall J. , (DIAN), for the Dominantly Inherited Alzheimer Network, Wang, Qing , Cruchaga, Carlos , Jack, Clifford R , Gordon, Brian A , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Cash, David M , Berman, Sarah , McCarthy, John Edward , Jucker, Mathias , Schofield, Peter R. , Brickman, Adam M. , Brooks, William S. , Ghetti, Bernardino , Koeppe, Robert A. , Su, Yi , Weiner, Michael W. , Wáng, Qīng , Xiong, Chengjie , Karch, Celeste M. , McDade, Eric , Benzinger, Tammie L.S. , Ances, Beau M. , (DIAN), for the Dominantly Inherited Alzheimer Network, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | January 21, 2021 | Volume: 17 | Issue: 6 | Pages: 1005-1016

10.1002/alz.12259 | PMID 33480178 Get It

AbstractIntroductionMachine learning models were used to discover novel disease trajectories for autosomal dominant Alzheimer's disease.MethodsLongitudinal structural magnetic resonance imaging, amyloid positron emission tomography (PET), and fluorodeoxyglucose PET were acquired in 131 mutation carriers and 74 non‐carriers from the Dominantly Inherited Alzheimer Network; the groups were matched for age, education, sex, and apolipoprotein ε4 (APOE ε4). A deep neural network was trained to predict disease progression for each modality. Relief algorithms identified the strongest predictors of mutation status.ResultsThe Relief algorithm identified the caudate, cingulate, and precuneus as the strongest predictors among all modalities. The model yielded accurate results for predicting future Pittsburgh compound B (R2 = 0.95), fluorodeoxyglucose (R2 = 0.93), and atrophy (R2 = 0.95) in mutation carriers compared to non‐carriers.DiscussionResults suggest a sigmoidal trajectory for amyloid, a biphasic response for metabolism, and a gradual decrease in volume, with disease progression primarily in subcortical, middle frontal, and posterior parietal regions.
Whole‐body senescent cell clearance alleviates age‐related brain inflammation and cognitive impairment in mice
Ogrodnik, Mikołaj , Evans, Shane A., Fielder, Edward , Victorelli, Stella , Krüger, Patrick, Salmonowicz, Hanna , Weigand, Bettina M., Patel, Ayush , Pirtskhalava, Tamar , Inman, Christine, Johnson, Kurt O. , Dickinson, Stephanie , Rocha, Azucena, Schafer, Marissa , Zhu, Yi , Passos, João F. , Kirkland, James L. , Jurk, Diana , Patel, Ayush D, Inman, Christine L, Schafer, Marissa J, Jurk, Diana , Passos, João F , Schafer, Marissa J , Zhu, Yi , Allison, David B. , Zglinicki, Thomas von , LeBrasseur, Nathan K. , Tchkonia, Tamar , Neretti, Nicola

Mayo Clinic

Aging Cell | January 20, 2021 | Volume: 20 | Issue: 2 | Pages: No page available

10.1111/acel.13296 | PMID 33470505 Get It

Abstract Cellular senescence is characterized by an irreversible cell cycle arrest and a pro‐inflammatory senescence‐associated secretory phenotype (SASP), which is a major contributor to aging and age‐related diseases. Clearance of senescent cells has been shown to improve brain function in mouse models of neurodegenerative diseases. However, it is still unknown whether senescent cell clearance alleviates cognitive dysfunction during the aging process. To investigate this, we first conducted single‐nuclei and single‐cell RNA‐seq in the hippocampus from young and aged mice. We observed an age‐dependent increase in p16 Ink4a senescent cells, which was more pronounced in microglia and oligodendrocyte progenitor cells and characterized by a SASP. We then aged INK ‐ ATTAC mice, in which p16 Ink4a ‐positive senescent cells can be genetically eliminated upon treatment with the drug AP20187 and treated them either with AP20187 or with the senolytic cocktail Dasatinib and Quercetin. We observed that both strategies resulted in a decrease in p16 Ink4a exclusively in the microglial population, resulting in reduced microglial activation and reduced expression of SASP factors. Importantly, both approaches significantly improved cognitive function in aged mice. Our data provide proof‐of‐concept for senolytic interventions' being a potential therapeutic avenue for alleviating age‐associated cognitive impairment.
Anesthesiology Residents’ Experiences and Perspectives of Residency Training
Chen, Dandan , Zhou, Yan , Nemergut, Edward C., Macario, Alex, Keegan, Mark T. , Sun, Huaping , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | January 14, 2021 | Volume: 132 | Issue: 4 | Pages: 1120-1128

10.1213/ane.0000000000005316 | PMID 33438965 Get It

BACKGROUND: Anesthesiology residents’ experiences and perspectives about their programs may be helpful in improving training. The goals of this repeated cross-sectional survey study are to determine: (1) the most important factors residents consider in choosing an anesthesiology residency, (2) the aspects of the clinical base year that best prepare residents for anesthesia clinical training, and what could be improved, (3) whether residents are satisfied with their anesthesiology residency and what their primary struggles are, and (4) whether residents believe their residency prepares them for proficiency in the 6 Accreditation Council for Graduate Medical Education (ACGME) Core Competencies and for independent practice. METHODS: Anesthesiologists beginning their US residency training from 2013 to 2016 were invited to participate in anonymous, confidential, and voluntary self-administered online surveys. Resident cohort was defined by clinical anesthesia year 1, such that 9 survey administrations were included in this study—3 surveys for the 2013 and 2014 cohorts (clinical anesthesia years 1–3), 2 surveys for the 2015 cohort (clinical anesthesia years 1–2), and 1 survey for the 2016 cohort (clinical anesthesia year 1). RESULTS: The overall response rate was 36% (4707 responses to 12,929 invitations). On a 5-point Likert scale with 1 as “very unimportant” and 5 as “very important,” quality of clinical experience (4.7–4.8 among the cohorts) and departmental commitment to education (4.3–4.5) were rated as the most important factors in anesthesiologists’ choice of residency. Approximately 70% of first- and second-year residents agreed that their clinical base year prepared them well for anesthesiology residency, particularly clinical training experiences in critical care rotations, anesthesiology rotations, and surgery rotations/perioperative procedure management. Overall, residents were satisfied with their choice of anesthesiology specialty (4.4–4.5 on a 5-point scale among cohort-training levels) and their residency programs (4.0–4.1). The residency training experiences mostly met their expectations (3.8–4.0). Senior residents who reported any struggles highlighted academic more than interpersonal or technical difficulties. Senior residents generally agreed that the residency adequately prepared them for independent practice (4.1–4.4). Of the 6 ACGME Core Competencies, residents had the highest confidence in professionalism (4.7–4.9) and interpersonal and communication skills (4.6–4.8). Areas in residency that could be improved include the provision of an appropriate balance between education and service and allowance for sufficient time off to search and interview for a postresidency position. CONCLUSIONS: Anesthesiology residents in the United States indicated they most value quality of clinical training experiences and are generally satisfied with their choice of specialty and residency program.
Corticotroph tumor progression after bilateral adrenalectomy (Nelson’s syndrome): systematic review and expert consensus recommendations
Reincke, Martín , Assié, Guillaume , Buchfelder, Michael , Ceccato, Filippo , Daniele, Andrea, Detomas, Mario , Dalmazi, Guido Di , Findling, James W. , Grossman, Ashley , Gomez-Sanchez, Celso E, Heaney, Anthony P. , Honegger, J. , Laws, Edward R. , Murakami, Masanori , Newell‐Price, John , Giraldi, Francesca Pecori , Perez‐Rivas, Luis Gustavo , Rainey, William E. , Schopohl, Jochen , Theodoropoulou, Marily , Rossum, Elisabeth F. C. van , Zacharieva, Sabina , Ritzel, Katrin , Ceccato, Filippo , Karavitaki, Niki , Lacroix, Andre , Pecori Giraldi, Francesca , Newell-Price, John , Murakami, Masanori , Albani, Adriana , Bancos, Irina , Brue, Thierry Christian , Chabre, Olivier , Elenkova, Atanaska P. , Karavitaki, Niki , Lacroix, André , Losa, Marco , Pivonello, Rosario , Sbiera, Silviu , Stratakis, Constantine A. , Valassi, Elena , Rubinstein, German

Mayo Clinic

European Journal of Endocrinology | January 12, 2021 | Volume: 184 | Issue: 3 | Pages: P1-P16

10.1530/eje-20-1088 | PMID 33444221 Get It

Background Corticotroph tumor progression (CTP) leading to Nelson’s syndrome (NS) is a severe and difficult-to-treat complication subsequent to bilateral adrenalectomy (BADX) for Cushing’s disease. Its characteristics are not well described, and consensus recommendations for diagnosis and treatment are missing. Methods A systematic literature search was performed focusing on clinical studies and case series (≥5 patients). Definition, cumulative incidence, treatment and long-term outcomes of CTP/NS after BADX were analyzed using descriptive statistics. The results were presented and discussed at an interdisciplinary consensus workshop attended by international pituitary experts in Munich on October 28, 2018. Results Data covered definition and cumulative incidence (34 studies, 1275 patients), surgical outcome (12 studies, 187 patients), outcome of radiation therapy (21 studies, 273 patients), and medical therapy (15 studies, 72 patients). Conclusions We endorse the definition of CTP-BADX/NS as radiological progression or new detection of a pituitary tumor on thin-section MRI. We recommend surveillance by MRI after 3 months and every 12 months for the first 3 years after BADX. Subsequently, we suggest clinical evaluation every 12 months and MRI at increasing intervals every 2–4 years (depending on ACTH and clinical parameters). We recommend pituitary surgery as first-line therapy in patients with CTP-BADX/NS. Surgery should be performed before extrasellar expansion of the tumor to obtain complete and long-term remission. Conventional radiotherapy or stereotactic radiosurgery should be utilized as second-line treatment for remnant tumor tissue showing extrasellar extension